Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + docetaxel and gut microbiota evolution in non-small cell lung cancer
ChiCTR2500098959Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Mar 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoints: Progression-free survival and Evolution of intestinal flora. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500098959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098959.